Basic Information
| LncRNA/CircRNA Name | lnc-MX1-1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR, RNAi etc. |
| Sample | prostate cancer tissues, cell lines (VCaP, LNCaP, 22Rv1, PC3, DU145) |
| Expression Pattern | up-regulated |
| Function Description | In the present study, we identified that lncRNA lnc-MX1-1 is over-expressed in prostate cancer tissues compared with their adjacent normal prostate tissues by gene expression array profiling. The expression of lnc-MX1-1 in 60 prostate cancer cases was determined by real-time quantitative PCR and the correlations between lnc-MX1-1 expression and patients' clinical features were further analyzed. |
| Pubmed ID | 26797523 |
| Year | 2016 |
| Title | Long non-coding RNA lnc-MX1-1 is associated with poor clinical features and promotes cellular proliferation and invasiveness in prostate cancer. |
External Links
| Links for lnc-MX1-1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |